The Federal Circuit is set to hear a significant lineup of cases in June, with implications for both the intellectual property and pharmaceuticals sectors. Among the most notable is the case involving an attempt to revive and enlarge a previously dismissed $64 million trade secrets judgment against Goodyear. This case will likely attract keen interest due to its potential impact on trade secrets litigation.
In the pharmaceutical arena, a clash between Acorda and Alkermes is raising pivotal questions about the financial ramifications for licensees paying royalties on patents that have expired. Specifically, the dispute centers on whether these licensees are entitled to refunds through arbitration, a matter that could set new precedents for licensing agreements and royalty payments.
These cases promise to shape the legal contours of their respective fields and highlight the dynamic nature of litigation at the Federal Circuit. For more details on these and other notable cases this June, please refer to the original article on Law360.